Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Arca Biopharma Inc (NQ: ABIO )

3.440 USD +0.140 (+4.24%)
Official Closing Price Updated: 7:50 PM EDT, Apr 21, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Arca Biopharma Inc

< Previous 1 2 3 Next >
ARCA biopharma Announces 2020 Financial Results and Provides Corporate Update
From GlobeNewswire News Releases
ARCA biopharma Announces First Patients Enrolled in ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 (AB201) as a Potential Treatment for COVID-19
From GlobeNewswire News Releases
ARCA biopharma Announces Location Change for 2020 Annual Meeting of Stockholders
From GlobeNewswire News Releases
AB201 Development as a Potential Treatment for COVID-19 Receives U.S. FDA Fast Track Designation
From GlobeNewswire News Releases
ARCA biopharma Announces Third Quarter 2020 Financial Results and Provides Corporate Update
From GlobeNewswire News Releases
ARCA biopharma Announces FDA Approval of IND Application for AB201 as a Potential Treatment for COVID-19
From GlobeNewswire News Releases
ARCA biopharma Announces Promotion of Chief Medical Officer and Vice President, Regulatory Affairs & Quality
From GlobeNewswire News Releases
ARCA biopharma Announces Submission of IND Application to U.S. FDA for AB201 as a Potential Treatment for COVID-19
From GlobeNewswire News Releases
ARCA Biopharma Announces Completion of FDA Pre-IND Consultation Under Coronavirus Treatment Acceleration Program for AB201 as a Potential Treatment for Severe COVID-19
From ACCESSWIRE
A Review Of Changes In Institutional Ownership: $BCDA $POAI $ABIO
Tags The Market Signal
From The Market Signal
Arca Biopharma Announces Second Quarter 2020 Financial Results and Provides Corporate Update
From GlobeNewswire News Releases
SARS-CoV-2 Cell Entry Mechanisms in Intact Human Heart Published in JACC: Basic to Translational Science by University of Colorado Anschutz Medical Campus and ARCA biopharma Investigators
From GlobeNewswire News Releases
ARCA biopharma Announces Closing of $6.1 Million Registered Direct Offering
From GlobeNewswire News Releases
ARCA Biopharma Announces $9.4 Million Registered Direct Offering
From GlobeNewswire News Releases
NetworkNewsBreaks – ARCA Biopharma, Inc. (NASDAQ: ABIO) Launches New Development Program to Evaluate AB201 for Treatment of COVID-19 Associated CAC
From InvestorBrandNetwork
ARCA biopharma Announces AB201 Development Program for Treatment of COVID-19 Associated Coagulopathy
From GlobeNewswire News Releases
Clinical Data Evaluating Gencaro for the Treatment of Atrial Fibrillation in Heart Failure Patients Featured in Three Presentations at the 2020 Heart Rhythm Scientific Sessions
From GlobeNewswire News Releases
ARCA Biopharma Announces First Quarter 2020 Financial Results And Provides Corporate Update
From GlobeNewswire News Releases
ARCA biopharma Announces Fiscal Year 2019 Financial Results and Provides Corporate Update
From GlobeNewswire News Releases
ARCA Biopharma Announces Third Quarter 2019 Financial Results and Provides Corporate Update
From GlobeNewswire News Releases
ARCA Biopharma President and CEO Dr. Michael Bristow to Present at HFSA 2019 Excellence in Translational Science Symposium
From GlobeNewswire News Releases
Arca Biopharma Announces Gencaro Atrial Fibrillation Clinical Data Selected for Presentation at HFSA 2019 Scientific Meeting
From GlobeNewswire News Releases
INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Abiomed, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
From GlobeNewswire News Releases
ARCA biopharma Announces Second Quarter 2019 Financial Results and Provides Corporate Update
From GlobeNewswire News Releases
ARCA biopharma Announces Submission of Patent Application to U.S. Patent and Trademark Office Covering Treatment of Atrial Fibrillation in Patients With Heart Failure
Similar Applications to Be Filed in Europe, Canada, Japan and China 
From GlobeNewswire News Releases
ARCA Biopharma Announces First Quarter 2019 Financial Results and Provides Corporate Update
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today reported... 
From GlobeNewswire News Releases
Thinking about buying stock in Arca Biopharma, Cronos Group, Nio Inc., Precipio, or Square?
InvestorsObserver issues critical PriceWatch Alerts for ABIO, CRON, NIO, PRPO, and SQ. 
From PR Newswire
GENETIC-AF Phase 2B Trial Results Published in the Journal of American College of Cardiology: Heart Failure
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that... 
From GlobeNewswire News Releases
ARCA biopharma Announces Steering Committee of Leading International Cardiology and Electrophysiology Experts for PRECISION-AF Phase 3 Clinical Trial
Steering Committee to Provide Scientific Oversight and Guidance for Pivotal Phase 3 Trial Evaluating Gencaro as Potentially the First Genetically-Targeted Treatment for Atrial Fibrillation 
From GlobeNewswire News Releases
Identification of Phosphodiesterease 3A Polymorphism With Potential to Increase Effectiveness of PDE3 Inhibitors Published in the Journal of the American College of Cardiology
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that... 
From GlobeNewswire News Releases
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.